S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
US Dollar Replaced By "Biden Bucks"? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
3rd Massive Dollar Upheaval Has Started (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
US Dollar Replaced By "Biden Bucks"? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
3rd Massive Dollar Upheaval Has Started (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
US Dollar Replaced By "Biden Bucks"? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
3rd Massive Dollar Upheaval Has Started (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,210.24
DOW   33,309.51
QQQ   325.93
The How And Why of Investing in Oil Stocks
US Dollar Replaced By "Biden Bucks"? (Ad)
The How and Why of Investing in Gold Stocks
Workhorse Group Is Ready To Get Back On The Horse 
A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
3rd Massive Dollar Upheaval Has Started (Ad)
Trump says he took the Fifth in NY civil investigation
Closing prices for crude oil, gold and other commodities
Wall Street roars after inflation cools more than expected
Biden's Plan to Confiscate Your Cash? (Ad)

Abeona Therapeutics - ABEO Stock Forecast, Price & News

$4.16
+0.21 (+5.32%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.90
$4.21
50-Day Range
$3.80
$5.56
52-Week Range
$3.26
$34.00
Volume
266,545 shs
Average Volume
110,416 shs
Market Capitalization
$24.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.50

Abeona Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
1,402.4% Upside
$62.50 Price Target
Short Interest
Healthy
3.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
1.88mentions of Abeona Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$5,600 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.50) to ($2.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

217th out of 1,108 stocks

Pharmaceutical Preparations Industry

93rd out of 542 stocks

ABEO stock logo

About Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Abeona Therapeutics Trading Up 5.3 %

Shares of NASDAQ:ABEO traded up $0.21 during trading on Wednesday, reaching $4.16. The company had a trading volume of 266,545 shares, compared to its average volume of 110,416. Abeona Therapeutics has a twelve month low of $3.26 and a twelve month high of $34.00. The stock has a market capitalization of $24.44 million, a PE ratio of -0.20 and a beta of 1.06. The stock has a 50-day moving average price of $4.39 and a two-hundred day moving average price of $5.52.

Abeona Therapeutics (NASDAQ:ABEO - Get Rating) last released its quarterly earnings results on Friday, May 13th. The biopharmaceutical company reported ($2.50) earnings per share for the quarter, missing analysts' consensus estimates of ($2.00) by ($0.50). The firm had revenue of $0.35 million during the quarter. On average, sell-side analysts predict that Abeona Therapeutics will post -3.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Abeona Therapeutics in a report on Friday, July 8th. They issued a "sell" rating for the company.

Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ABEO Stock News Headlines

Abeona Therapeutics Inc. (ABEO)
See More Headlines
Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ABEO Company Calendar

Last Earnings
5/13/2022
Today
8/10/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$62.50
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+1,402.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-84,940,000.00
Pretax Margin
-2,681.56%

Debt

Sales & Book Value

Annual Sales
$3 million
Book Value
$8.73 per share

Miscellaneous

Free Float
5,733,000
Market Cap
$24.44 million
Optionable
Optionable
Beta
1.06

Key Executives

  • Mr. Steven H. Rouhandeh (Age 61)
    Exec. Chairman
  • Dr. Timothy J. Miller (Age 46)
    Pres, Chief Scientific Officer & Director
  • Mr. Jeffrey Blaine Davis (Age 55)
    Chief Operating Officer
  • Mr. Carsten Thiel (Age 54)
    Chief Exec. Officer
  • Mr. Stephen B. Thompson (Age 64)
    Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer













ABEO Stock - Frequently Asked Questions

Should I buy or sell Abeona Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares.
View ABEO analyst ratings
or view top-rated stocks.

What is Abeona Therapeutics' stock price forecast for 2022?

3 brokers have issued twelve-month price targets for Abeona Therapeutics' shares. Their ABEO share price forecasts range from $25.00 to $100.00. On average, they predict the company's share price to reach $62.50 in the next year. This suggests a possible upside of 1,402.4% from the stock's current price.
View analysts price targets for ABEO
or view top-rated stocks among Wall Street analysts.

How have ABEO shares performed in 2022?

Abeona Therapeutics' stock was trading at $8.4250 at the beginning of 2022. Since then, ABEO shares have decreased by 50.6% and is now trading at $4.16.
View the best growth stocks for 2022 here
.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) released its quarterly earnings results on Friday, May, 13th. The biopharmaceutical company reported ($2.50) earnings per share for the quarter, missing analysts' consensus estimates of ($2.00) by $0.50. The biopharmaceutical company had revenue of $0.35 million for the quarter.

When did Abeona Therapeutics' stock split?

Abeona Therapeutics shares reverse split on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Abeona Therapeutics own?

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

How do I buy shares of Abeona Therapeutics?

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $4.16.

How much money does Abeona Therapeutics make?

Abeona Therapeutics (NASDAQ:ABEO) has a market capitalization of $24.44 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-84,940,000.00 in net income (profit) each year or ($20.50) on an earnings per share basis.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The official website for the company is www.abeonatherapeutics.com. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at ir@abeonatherapeutics.com, or via fax at 214-905-5101.

This page (NASDAQ:ABEO) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.